Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 19/20 | 0.71 |
| ▸ | BACE2 | Q9Y5Z0 | 11/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4078021 | 0.83 | BACE1 (1.00) | BACE1BACE2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4078136 | 0.79 | BACE1 (0.44) | BACE1BACE2 | |
| SCHEMBL4078985 | 0.77 | BACE1 (0.39) | BACE1BACE2RAB9A | |
| SCHEMBL4083464 | 0.77 | BACE1 (0.81) | BACE1BACE2 | |
| SCHEMBL18636674 | 0.76 | BACE1 (0.61) | BACE1BACE2 | |
| SCHEMBL4083288 | 0.74 | BACE1 (0.84) | BACE1BACE2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4078652 | 0.73 | BACE1 (1.00) | BACE1BACE2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4088724 | 0.73 | BACE1 (0.78) | BACE1BACE2 | |
| SCHEMBL18636958 | 0.72 | BACE1 (0.65) | BACE1BACE2 | |
| SCHEMBL10155190 | 0.71 | BACE1 (0.82) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168630-B2 | Aminodihydrothiazine derivatives substituted with a cyclic group | SHIONOGI & CO., LTD. (JP) | 2012-05-01 | — | — | US | disclosed |
| US-20100075957-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | SHIONOGI & CO., LTD. (JP) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075957-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | APP, IAPP, APBA1 | BACE1 5/4885BACE2 14/4885NPC1 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.